Growth InvestmentsSlowing top line momentum coupled with lower margins due to ongoing growth investments, especially in marketing, would be taken negatively.
Profitability ConcernsThe intensified marketing efforts for Rx also came at a cost of slightly lower profitability in FY24.
Sales PerformanceGerman Rx sales showed a sequential slowdown, with only €6m incremental sales.